Phase I/II study of rilotumumab (AMG 102), an HGF inhibitor, and erlotinib in patients with advanced non-small cell lung cancer

BACKGROUND: Activation of MET and its ligand hepatocyte growth factor (HGF) are implicated in resistance to epidermal growth factor receptor (EGFR) inhibitors. This Phase I/II trial evaluated rilotumumab (anti-HGF antibody), combined with erlotinib, in patients with metastatic previously treated NSC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Tarhini, Ahmad A, Rafique, Imran, Floros, Theofanis, Tran, Phu, Gooding, William, Villaruz, Liza, Burns, Timothy, Friedland, David, Petro, Daniel, Farooqui, Mariya, Gomez-Garcia, Jose, Gaither-Davis, Autumn, Dacic, Sanja, Argiris, Athanassios, Socinski, Mark A, Stabile, Laura P., Siegfried, Jill M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5517339/
https://ncbi.nlm.nih.gov/pubmed/28472537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30717
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados